SEC Company Response from Regen BioPharma Inc (RGBP, RGBPP) (CIK 0001589150) (RGBP) — Mar 4, 2014
Regen BioPharma Inc (RGBP, RGBPP) (CIK 0001589150)
Date: March 4, 2014 · CIK: 0001589150 · Accession: 0001554795-14-000151
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-191725
Letter
Division of Corporation Finance Securities and Exchange Commission 100 F. Street, N.E. Washington, DC 20549 Re: Regen Biopharma, Inc. Registration Statement on Form S-1, as amended (Registration No. 333-191725)
Dear Ms. Hayes
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Regen Biopharma, Inc., a Nevada corporation (the “Company”), hereby requests that the effectiveness of its Registration Statement on Form S-1, as amended (Registration No. 333-191725), be accelerated so that it will become effective at 9:00 AM Eastern Standard Time on March 18, 2014, or as soon thereafter as practicable.
The Company hereby acknowledges that:
·
Should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
·
The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
·
The Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
REGEN BIOPHARMA, INC.
Show Raw Text
CORRESP
1
filename1.htm
REGEN
BIOPHARMA, INC.
4700
SPRING STREET, SUITE 304,
LA
MESA, CALIFORNIA, 91942
March
4, 2014
BY EDGAR
Suzanne Hayes
Assistant Director
Division of Corporation
Finance
Securities and Exchange
Commission
100 F. Street, N.E.
Washington, DC 20549
Re:
Regen Biopharma, Inc.
Registration Statement on Form S-1, as amended (Registration No. 333-191725)
Dear Ms. Hayes
Pursuant to Rule 461
of the General Rules and Regulations under the Securities Act of 1933, as amended, Regen Biopharma, Inc., a Nevada corporation
(the “Company”), hereby requests that the effectiveness of its Registration Statement on Form S-1, as amended (Registration
No. 333-191725), be accelerated so that it will become effective at 9:00 AM Eastern Standard Time on March 18, 2014, or as soon
thereafter as practicable.
The Company hereby
acknowledges that:
·
Should
the Securities and Exchange Commission (the “Commission”)
or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking
any action with respect to the filing;
·
The action of the Commission or the
staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility
for the adequacy and accuracy of the disclosure in the filing; and
·
The Company may not assert staff comments
and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal
securities laws of the United States.
Very truly yours,
REGEN BIOPHARMA, INC.
By:
/s/ David Koos
Chief
Executive Officer